Abstract
Since the publication of the European League Against Rheumatism recommendations for the pharmacological treatment of psoriatic arthritis (PsA) in 2012, new evidence and new therapeutic agents have emerged. The objective was to update these recommendations.
Original language | English |
---|---|
Pages (from-to) | 499-510 |
Journal | Annals of the Rheumatic Diseases |
Volume | 75 |
Issue number | 3 |
Early online date | 2015 Dec 7 |
DOIs | |
Publication status | Published - 2016 |
Subject classification (UKÄ)
- Rheumatology and Autoimmunity